-
1
-
-
77956458957
-
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
-
Hesketh P.J., Aapro M., Street J.C., Carides A.D. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 2010, 18:1171-1177.
-
(2010)
Support Care Cancer
, vol.18
, pp. 1171-1177
-
-
Hesketh, P.J.1
Aapro, M.2
Street, J.C.3
Carides, A.D.4
-
2
-
-
0032992455
-
Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice
-
Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999, 4:191-196.
-
(1999)
Oncologist
, vol.4
, pp. 191-196
-
-
Hesketh, P.J.1
-
3
-
-
77954345456
-
Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Schmoll H.J., Jordan K., Huddart R., et al. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v140-v146.
-
(2010)
Ann Oncol
, vol.21
-
-
Schmoll, H.J.1
Jordan, K.2
Huddart, R.3
-
4
-
-
77954322183
-
Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Okines A., Verheij M., Allum W., Cunningham D., Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v50-v54.
-
(2010)
Ann Oncol
, vol.21
-
-
Okines, A.1
Verheij, M.2
Allum, W.3
Cunningham, D.4
Cervantes, A.5
-
5
-
-
77954340426
-
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Colombo N., Peiretti M., Parma G., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v23-v30.
-
(2010)
Ann Oncol
, vol.21
-
-
Colombo, N.1
Peiretti, M.2
Parma, G.3
-
6
-
-
77954319884
-
Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Haie-Meder C., Morice P., Castiglione M. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v37-v40.
-
(2010)
Ann Oncol
, vol.21
-
-
Haie-Meder, C.1
Morice, P.2
Castiglione, M.3
-
7
-
-
0347816226
-
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group
-
Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol 2003, 21:4112-4119.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4112-4119
-
-
Hesketh, P.J.1
Grunberg, S.M.2
Gralla, R.J.3
-
8
-
-
0038728753
-
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America
-
Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
-
(2003)
Cancer
, vol.97
, pp. 3090-3098
-
-
Poli-Bigelli, S.1
Rodrigues-Pereira, J.2
Carides, A.D.3
-
9
-
-
21044434743
-
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
-
Warr D.G., Hesketh P.J., Gralla R.J., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2822-2830
-
-
Warr, D.G.1
Hesketh, P.J.2
Gralla, R.J.3
-
10
-
-
33745515076
-
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
-
Kris M.G., Hesketh P.J., Somerfield M.R., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006, 24:2932-2947.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2932-2947
-
-
Kris, M.G.1
Hesketh, P.J.2
Somerfield, M.R.3
-
11
-
-
77954319603
-
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
-
Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21:v232-v243.
-
(2010)
Ann Oncol
, vol.21
-
-
Roila, F.1
Herrstedt, J.2
Aapro, M.3
-
12
-
-
84870494170
-
-
National Comprehensive Cancer Network. Clinical practice guidelines in oncology - V.1.2012: antiemesis. Available from:
-
National Comprehensive Cancer Network. Clinical practice guidelines in oncology - V.1.2012: antiemesis. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
-
-
-
-
13
-
-
77952480785
-
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
-
Rapoport B.L., Jordan K., Boice J.A., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010, 18:423-431.
-
(2010)
Support Care Cancer
, vol.18
, pp. 423-431
-
-
Rapoport, B.L.1
Jordan, K.2
Boice, J.A.3
-
14
-
-
20444482460
-
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials
-
Warr D.G., Grunberg S.M., Gralla R.J., et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005, 41:1278-1285.
-
(2005)
Eur J Cancer
, vol.41
, pp. 1278-1285
-
-
Warr, D.G.1
Grunberg, S.M.2
Gralla, R.J.3
-
15
-
-
80755126820
-
Antiemetics: American Society of Clinical Oncology clinical practice guideline update
-
Basch E., Prestrud A.A., Hesketh P.J., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4189-4198
-
-
Basch, E.1
Prestrud, A.A.2
Hesketh, P.J.3
-
16
-
-
84869083097
-
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer
-
[Abstract 1116]
-
Webb T., Hardwick J., Carides A.D., Street J.C. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer. Cancer Res 2010, 69. [Abstract 1116].
-
(2010)
Cancer Res
, vol.69
-
-
Webb, T.1
Hardwick, J.2
Carides, A.D.3
Street, J.C.4
-
17
-
-
33646412299
-
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
-
Hesketh P.J., Grunberg S.M., Herrstedt J., et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006, 14:354-360.
-
(2006)
Support Care Cancer
, vol.14
, pp. 354-360
-
-
Hesketh, P.J.1
Grunberg, S.M.2
Herrstedt, J.3
-
18
-
-
80051582732
-
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)
-
Hesketh P.J., Warr D.G., Street J.C., Carides A.D. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer 2011, 19:1297-1302.
-
(2011)
Support Care Cancer
, vol.19
, pp. 1297-1302
-
-
Hesketh, P.J.1
Warr, D.G.2
Street, J.C.3
Carides, A.D.4
-
19
-
-
79951774253
-
Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1872 patients (pts) in prospective randomized clinical phase III trials (RCTs)
-
Gralla R.J., Rapoport B.L., Jordan K., Street J.C., Carides A. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1872 patients (pts) in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 2010, 28:9057.
-
(2010)
J Clin Oncol
, vol.28
, pp. 9057
-
-
Gralla, R.J.1
Rapoport, B.L.2
Jordan, K.3
Street, J.C.4
Carides, A.5
-
20
-
-
84863446959
-
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
-
Hesketh P.J., Sanz-Altamira P., Bushey J., Hesketh A.M. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012, 20:1043-1047.
-
(2012)
Support Care Cancer
, vol.20
, pp. 1043-1047
-
-
Hesketh, P.J.1
Sanz-Altamira, P.2
Bushey, J.3
Hesketh, A.M.4
|